Dominion Energy (D) and its predecessors have delivered energy since 1898. Today the company is one of America's largest diversified utilities with a customer base of 7.5 million gas and electric customers in 18 states. In recent years Dominion has grown through various acquisitions including its 2016 purchase of Questar (natural gas distributor) for $5.9 billion and its $14.6 billion acquisition of SCANA (regulated gas and electric utility in South Carolina) which closed in January 2019. The firm also completed the roll-up of its midstream MLP, Dominion Midstream Partners, in January 2019. The company's earnings are diversified by both region and business focus:

Many companies grow through acquisitions, but Wall Street is often skeptical of big deals given the risks involved. In May 2018, International Flavors & Fragrances (IFF) announced it was buying rival Frutarom in a $7.1 billion cash-and-stock deal. Given that IFF's market cap at the time was just over $12 billion, this qualified as a big acquisition. Investors didn't like it. IFF's share price fell over 10% on the news, causing some dividend growth investors to worry about what this merger might mean for the company's long-term outlook. The acquisition will finally be reflected on IFF's books when it reports earnings later this week, so let's take a look at whether or not this deal seems to makes sense for IFF and [...]

Founded in 1885, Johnson & Johnson (JNJ) is the world’s largest medical conglomerate. With more than 250 subsidiaries operating in over 60 countries, Johnson & Johnson’s three major business units provide it with a diversified mix of revenue, earnings, and cash flow. Here are the company’s operating segments: Pharmaceuticals (50% of sales, 61% of pretax profits): dozens of patented drugs and vaccines to treat oncology, cardiovascular, immunological, neurological, and infectious diseases, and diabetes. Remicade, a treatment for a number of immune-mediated inflammatory diseases, is Johnson & Johnson’s largest drug and accounted for 6.5% of company-wide revenue in 2018. Medical Devices (33% of sales, 29% of pretax profits): surgical, orthopedic, endomechanical (i.e. hip replacements), and sterilization equipment. Consumer Products (17% of sales, 10% [...]

Founded in 1849, Pfizer (PFE) is one of the world's largest drugmakers, with medications sold in over 125 countries. The company's annual sales exceed $50 billion and are grouped into three business segments: Pfizer Biopharmaceuticals (56% of sales): produces patented medicines to treat various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases. This unit drives Pfizer's overall growth because it produces all of the company's largest sellers, including a number of medications with more than $1 billion in annual sales. Compared to other pharma and biotech companies, Pfizer's portfolio is nicely diversified by treatment area and drug type, reducing its risk profile.